Cancer Therapeutics Maker, Boundless Bio, Drops 11% after $100M IPO
By
Amadeus Von Ziegler
1 min read
⚠️ Heads up: this article is from our "experimental era" — a beautiful mess of enthusiasm ✨, caffeine ☕, and user-submitted chaos 🤹. We kept it because it’s part of our journey 🛤️ (and hey, everyone has awkward teenage years 😅).
Shares of Boundless Bio Inc., a cancer therapeutics maker backed by Bayer AG, fell nearly 11% after raising $100 million in a US initial public offering. The San Diego-based company’s shares declined to $14.25 each on Thursday, below their IPO price of $16 — the midpoint of a $15 to $17 marketed range.